Plain-English translation of NCT07425535 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers want to understand how healthy eyes—those without glaucoma—respond when eye pressure is lowered using latanoprost, an FDA-approved eye drop medication. By measuring the physical changes in the optic nerve (the part of your eye that sends signals to your brain) before and during treatment with this medication, scientists hope to better understand the differences between healthy eyes and glaucomatous eyes. This comparison will help them develop better ways to diagnose and treat glaucoma.
Even though glaucoma is a serious eye disease, researchers don't fully understand how the eye's structure normally responds to pressure changes. By studying how healthy eyes react to this medication, they can create a 'normal baseline' to compare against glaucoma patients—which could lead to earlier detection and better treatment options.
You likely qualify if…
You likely don't qualify if…
You will use an eye drop medication called latanoprost for less than one month. During this time, researchers will take special pictures of your eyes at two different visits—once at the beginning (baseline) and once while you are using the medication—to measure how your eye's structure changes in response to the pressure-lowering effect. The study involves non-invasive imaging only; no surgery or injections are required.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Johns Hopkins University
Collaborators
National Eye Institute (NEI)
Enrollment target
~30 participants
Started
June 2026
Primary completion
March 2028
Age range
30 Years – 90 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Harry A Quigley, MD
Johns Hopkins University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.